These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25997147)

  • 21. IC31, a two-component novel adjuvant mixed with a conjugate vaccine enhances protective immunity against pneumococcal disease in neonatal mice.
    Olafsdottir TA; Lingnau K; Nagy E; Jonsdottir I
    Scand J Immunol; 2009 Mar; 69(3):194-202. PubMed ID: 19281531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in
    Bekker LG; Dintwe O; Fiore-Gartland A; Middelkoop K; Hutter J; Williams A; Randhawa AK; Ruhwald M; Kromann I; Andersen PL; DiazGranados CA; Rutkowski KT; Tait D; Miner MD; Andersen-Nissen E; De Rosa SC; Seaton KE; Tomaras GD; McElrath MJ; Ginsberg A; Kublin JG;
    EClinicalMedicine; 2020 Apr; 21():100313. PubMed ID: 32382714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prime-boost vaccination with Bacillus Calmette Guerin and a recombinant adenovirus co-expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis induces robust antigen-specific immune responses in mice.
    Li W; Li M; Deng G; Zhao L; Liu X; Wang Y
    Mol Med Rep; 2015 Aug; 12(2):3073-80. PubMed ID: 25962477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis.
    Li M; Yu DH; Cai H
    DNA Cell Biol; 2008 Aug; 27(8):405-13. PubMed ID: 18694298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenicity and protective efficacy conferred by a novel recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing interleukin-12p70 of human cytokine and Ag85A of Mycobacterium tuberculosis fusion protein.
    Deng YH; He HY; Zhang FJ
    Scand J Immunol; 2013 Dec; 78(6):497-506. PubMed ID: 24283772
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Developing a preventive immunization approach against insect bite hypersensitivity using recombinant allergens: A pilot study.
    Jonsdottir S; Hamza E; Janda J; Rhyner C; Meinke A; Marti E; Svansson V; Torsteinsdottir S
    Vet Immunol Immunopathol; 2015 Jul; 166(1-2):8-21. PubMed ID: 26004943
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Whole blood RNA signatures in tuberculosis patients receiving H56:IC31 vaccine as adjunctive therapy.
    Alonso-Rodríguez N; Vianello E; van Veen S; Jenum S; Tonby K; van Riessen R; Lai X; Mortensen R; Ottenhoff THM; Dyrhol-Riise AM
    Front Immunol; 2024; 15():1350593. PubMed ID: 38433842
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
    Wizel B; Persson J; Thörn K; Nagy E; Harandi AM
    Vaccine; 2012 Jun; 30(29):4361-8. PubMed ID: 22682292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
    Li Q; Yu H; Zhang Y; Wang B; Jiang W; Da Z; Xian Q; Wang Y; Liu X; Zhu B
    Scand J Immunol; 2011 Jun; 73(6):568-76. PubMed ID: 21323695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The in vivo expressed Mycobacterium tuberculosis (IVE-TB) antigen Rv2034 induces CD4⁺ T-cells that protect against pulmonary infection in HLA-DR transgenic mice and guinea pigs.
    Commandeur S; van den Eeden SJ; Dijkman K; Clark SO; van Meijgaarden KE; Wilson L; Franken KL; Williams A; Christensen D; Ottenhoff TH; Geluk A
    Vaccine; 2014 Jun; 32(29):3580-8. PubMed ID: 24837764
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fusion protein Ag85B-MPT64(190-198)-Mtb8.4 has higher immunogenicity than Ag85B with capacity to boost BCG-primed immunity against Mycobacterium tuberculosis in mice.
    Luo Y; Wang B; Hu L; Yu H; Da Z; Jiang W; Song N; Qie Y; Wang H; Tang Z; Xian Q; Zhang Y; Zhu B
    Vaccine; 2009 Oct; 27(44):6179-85. PubMed ID: 19712772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancement of antimycobacterial Th1-cell responses by a Mycobacterium bovis BCG prime-protein boost vaccination strategy.
    Lu M; Xia ZY; Bao L
    Cell Immunol; 2013; 285(1-2):111-7. PubMed ID: 24177251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and protective efficacy of novel Mycobacterium tuberculosis antigens.
    Derrick SC; Yabe IM; Yang A; Kolibab K; Hollingsworth B; Kurtz SL; Morris S
    Vaccine; 2013 Sep; 31(41):4641-6. PubMed ID: 23906890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adult-like anti-mycobacterial T cell and in vivo dendritic cell responses following neonatal immunization with Ag85B-ESAT-6 in the IC31 adjuvant.
    Kamath AT; Rochat AF; Valenti MP; Agger EM; Lingnau K; Andersen P; Lambert PH; Siegrist CA
    PLoS One; 2008; 3(11):e3683. PubMed ID: 18997860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nasal boost with adjuvanted heat-killed BCG or arabinomannan-protein conjugate improves primary BCG-induced protection in C57BL/6 mice.
    Haile M; Hamasur B; Jaxmar T; Gavier-Widen D; Chambers MA; Sanchez B; Schröder U; Källenius G; Svenson SB; Pawlowski A
    Tuberculosis (Edinb); 2005; 85(1-2):107-14. PubMed ID: 15687034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased levels of interferon-gamma primed by culture filtrate proteins antigen and CpG-ODN immunization do not confer significant protection against Mycobacterium tuberculosis infection.
    Fonseca DM; Silva CL; Paula MO; Soares EG; Marchal G; Horn C; Bonato VL
    Immunology; 2007 Aug; 121(4):508-17. PubMed ID: 17433075
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TLR4- and TLR9-dependent effects on cytokines, cell viability, and invasion in human bladder cancer cells.
    Olbert PJ; Kesch C; Henrici M; Subtil FS; Honacker A; Hegele A; Hofmann R; Hänze J
    Urol Oncol; 2015 Mar; 33(3):110.e19-27. PubMed ID: 25499923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone.
    Wedlock DN; Denis M; Skinner MA; Koach J; de Lisle GW; Vordermeier HM; Hewinson RG; van Drunen Littel-van den Hurk S; Babiuk LA; Hecker R; Buddle BM
    Infect Immun; 2005 Jun; 73(6):3540-6. PubMed ID: 15908383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX.
    Niu H; Hu L; Li Q; Da Z; Wang B; Tang K; Xin Q; Yu H; Zhang Y; Wang Y; Ma X; Zhu B
    Vaccine; 2011 Nov; 29(51):9451-8. PubMed ID: 22024175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new vaccine against tuberculosis shows greater protection in a mouse model with progressive pulmonary tuberculosis.
    Castañon-Arreola M; López-Vidal Y; Espitia-Pinzón C; Hernández-Pando R
    Tuberculosis (Edinb); 2005; 85(1-2):115-26. PubMed ID: 15687035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.